These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 11163826)

  • 1. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
    Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
    Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment.
    Kawamura N; Ito F; Ichimura T; Shibata S; Umesaki N; Ogita S
    Fertil Steril; 1997 Oct; 68(4):632-6. PubMed ID: 9341601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
    Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
    Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K; Kawamura N; Ishiko O; Ogita S
    Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
    Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
    Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.
    Chung YJ; Chae B; Kwak SH; Song JY; Lee AW; Jo HH; Lew YO; Kim JH; Kim MR
    Int J Med Sci; 2014; 11(3):276-81. PubMed ID: 24516352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings.
    Wang PH; Yang AH; Yuan CC; Lee WL; Chao HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Nov; 61(11):625-9. PubMed ID: 9872018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles.
    Palomba S; Affinito P; Di Carlo C; Bifulco G; Nappi C
    Fertil Steril; 1999 Nov; 72(5):889-95. PubMed ID: 10560995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones.
    Malik M; Britten J; Cox J; Patel A; Catherino WH
    Fertil Steril; 2016 Jan; 105(1):214-24. PubMed ID: 26409322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonists before surgery for uterine leiomyomas. A review.
    Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
    J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of the shrinking rate of uterine leiomyoma nodules using needle biopsy specimens.
    Kasai M; Ichimura T; Kawamura N; Sumikura T; Matsuda M; Asano C; Sumi T; Ishiko O
    Fertil Steril; 2012 Aug; 98(2):440-3. PubMed ID: 22749217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy.
    Palomba S; Pellicano M; Affinito P; Di Carlo C; Zullo F; Nappi C
    Fertil Steril; 2001 Feb; 75(2):429-33. PubMed ID: 11172852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
    Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
    Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin.
    Crow J; Gardner RL; McSweeney G; Shaw RW
    Int J Gynecol Pathol; 1995 Jul; 14(3):235-42. PubMed ID: 8600075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
    Britten JL; Malik M; Levy G; Mendoza M; Catherino WH
    Fertil Steril; 2012 Nov; 98(5):1299-307. PubMed ID: 22901846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience.
    Okuda S; Oshio K; Shinmoto H; Tanimoto A; Asada H; Fujii T; Yoshimura Y; Kuribayashi S
    Radiology; 2008 Sep; 248(3):917-24. PubMed ID: 18710984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
    Cheng YM; Chou CY; Huang SC; Lin HC
    BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.